IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: Stephen Douglas Barrett, et al.

EXAMINER:

SERIAL NO. : 10/031,037

ART UNIT

.]

FILED

: January 15, 2002

PAPER NO

FOR

: METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS

Statement as Provided by 37 CFR 1.97(b)

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

Dated: May 15, 2002

Suzanne M. Harvey

Registration No. 42,640

Warner-Lambert Company

2800 Plymouth Road Ann Arbor, MI 48105

Telephone: (734) 622-2658

Facsimile: (734) 622-1553

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0051

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMENCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB co

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

Col	mpl te if Known	到
Application Number	10/031037	77
Filing Date	January 15, 2002	3
First Named Inventor	Stephen Douglas Barrett, et	all
Group Art Unit		
Examiner Name		8
Attorney Docket Number	A0000102-01-SMH	7

U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	U.S. Patent Document Kind Code² (if known)		Name of Patentee or Applicant Of Cited Document Of Cited Document				
		5,155,1	10	David T. Connor, et al.	10/13/1992			
	\rightarrow							
								
		-						
								
			-					
				<u></u>				
					 			
								
			-	· · · · · · · · · · · · · · · · · · ·				
	-				 			
			- - 		 			

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite No.bff	ic e ³	Foreign Patent Do	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		wo	98/37881	Al	Alexander J. Bridges	09/03/1998		
		WC	00/35436	A2	David T. Dudley, et al.	06/22/2000		
		WO	00/42022	A1	Stephen D. Barrett, et al	07/20/2000		-
								土
								╀
								士
								$oxed{\bot}$

Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

USSN 10/031,037 Express Mail N

.EF220788517US PD-A0000102-01-SMH

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →	+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	ite for form 1449B/PT	0		Complete if Known		
				Application Number	10/031037	
INF	ORMATIO	N D	ISCLOSURE	Filing Date	January 15, 2002	
STA	TEMENT	RY	APPLICANT	First Named Inventor	Stephen Douglas Barrett, et al.	
U 17		٠.	/ (Group Art Unit		
	(use as many s	sheet	s as necessary)	Examiner Name		
Sheet 2 of 2				Attorney Docket Number	A0000102-01-SMH	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
		PCT International Search Report PCT/US00/18345				
	ļ	H. BEKEMEIER, et al., "Structure-Activity Relationship in Nonsteroidal Antinflammatory Agents, Including Qsar in Fenamate Derivatives", Agents and Actions Supplements, July 1, 1982, pp 17-34				
		J. V. DUNCIA, et al., "MEK Inhibitors: The Chemistry and Biological Activity of U0126, Its Analogs, and Cyclization Products", Bioorganic & Medicinal Chemistry Letters, 1998, pp 2839-2844, No. 8				
		N. S. DUESBERY, et al., "MEK Waars, a new front in the Battle Against Cancer", Nature Medicine, July 1999, pp 736-737, Vol. 5, No. 7				
	-	RU-RONG JI, et al., "Nociceptive-specific Activation of ERK in Spinal Neurons Contributes to Pain Hypersensitivity", Nature Neuroscience, December 1999, pp 1114-1119, Vol. 2, No. 12				
_						
,						
			_			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.